Citations

Clear

1422 citation(s) found for "White, JB".

Endovascular Treatment of Basilar Bifurcation Aneurysms With PulseRider-Assisted Coiling: 2-Dimensional Operative Video
Sattur, Mithun G. , Kasab, Sami Al , Spiotta, Alejandro M , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond, Veznedaroglu, Erol, Welch, Babu G. , White, Jonathan, Spiotta, Alejandro M , Schirmer, Clemens M , Porto, Guilherme , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael R. , Levy, Elad I. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Tawk, Rabih G. , Thomas, Ajith J , White, Jonathan A.

Mayo Clinic

Operative Neurosurgery | April 17, 2021 | Volume: 21 | Issue: 2 | Pages: E109-E110

10.1093/ons/opab102 | PMID 33861344 Get It

Abstract Wide-necked bifurcation aneurysms pose technical and anatomical challenges to endovascular treatment, which make the simpler assisted (balloon or single stent) coiling techniques less effective. 1 Consequently, unique endovascular solutions to treat such aneurysms have been devised. 2,3 One such device is PulseRider (Cerenovus, New Brunswick, New Jersey), which is designed to provide neck support for a coil mass while protecting the bifurcation. 3 The device comprises a body or stem that is deployed in the parent artery and a saddle component that sits at the aneurysm neck to keep the coil mass away from the bifurcation. There are several technical nuances involved in successful use of the device during positioning, deployment, and detachment. 3 We present a surgical video detailing the steps of PulseRider-assisted coiling of unruptured basilar bifurcation (or basilar apex) aneurysms. The first case highlights index treatment at diagnosis and the second showcases treatment of a recurrent basilar apex aneurysm. Both patients provided informed consent to the procedure. We also briefly discuss the rationale for treating basilar apex aneurysms. 4,5
Middle Cerebral Artery Thrombectomy: Clinical Findings and Technical Pearls: 2-Dimensional Operative Video
Rangwala, Shivani D. , Selvan, Pradeep, Tenser, Matthew, Mack, William J. , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , Schirmer, Clemens M , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael R. , Levy, Elad I. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Tawk, Rabih G. , Thomas, Ajith J , White, Jonathan Samuel

Mayo Clinic

Operative Neurosurgery | April 17, 2021 | Volume: 21 | Issue: 2 | Pages: E107-E108

10.1093/ons/opab101 | PMID 33861327 Get It

Abstract Mechanical thrombectomy as a treatment for large vessel occlusion to achieve rapid revascularization is supported in the literature. 1-3 The presenting symptoms will localize to functions of the ischemic area. The middle cerebral artery (MCA) supplies areas of the frontal, temporal, and parietal cortices, as well as the basal ganglia. Occlusion of the MCA will present with contralateral hemiplegia, sensory loss, and, if the dominant hemisphere is involved, language deficits. We present a right-hand-dominant 79-yr-old female with right MCA syndrome—her last known well time was 1.5 h prior to presentation. Her NIH (National Institutes of Health) Stroke Scale was 16, most notable for left hemiplegia. Although the patient presented early in the clinical time course, as part of our institution protocol, a computed tomography (CT) head, CT perfusion, and CT angiogram (CTA) were performed. CT head did not demonstrate acute hemorrhage, so she received intravenous tissue plasminogen activator. CTA demonstrated a right MCA occlusion and CT perfusion suggested a large area of salvageable tissue, so she was taken to the angiography suite for mechanical thrombectomy. Angiography of the right internal carotid artery (ICA) showed MCA occlusion (insular segment). A thrombectomy device was deployed over the area of occlusion and allowed to engage for 5 min. An aspiration catheter was advanced over the stentriever up against the clot. The stentriever device was withdrawn under continuous aspiration and follow-up angiography showed complete reperfusion. The patient demonstrated improvement and was eventually discharged to an inpatient rehabilitation center. Patient provided consent for photography per university protocol. Institutional review board (IRB) approval was not needed for the single-patient data included in this report.
Asymmetry of Hippocampal Tau Pathology in Primary Age-Related Tauopathy and Alzheimer Disease
Walker, Jamie M. , Fudym, Yelena, Farrell, Kurt , Iida, Megan A., Bieniek, Kevin F. , Crary, John F. , Richardson, Timothy E. , Farrell, Kurt , Seshadri, Sudha , White, Charles L.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | April 17, 2021 | Volume: 80 | Issue: 5 | Pages: 436-445

10.1093/jnen/nlab032 | PMID 33860327 Get It

Abstract Primary age-related tauopathy (PART) is a neurodegenerative entity defined as neurofibrillary degeneration generally restricted to the medial temporal region (Braak stage I–IV) with complete or near absence of diffuse and neuritic plaques. Symptoms range in severity but are generally milder and later in onset than in Alzheimer disease (AD). Recently, an early predilection for neurofibrillary degeneration in the hippocampal CA2 subregion has been demonstrated in PART, whereas AD neuropathologic change (ADNC) typically displays relative sparing of CA2 until later stages. In this study, we utilized a semiquantitative scoring system to evaluate asymmetry of neurofibrillary degeneration between left and right hippocampi in 67 PART cases and 17 ADNC cases. 49% of PART cases demonstrated asymmetric findings in at least one hippocampal subregion, and 79% of the asymmetric cases displayed some degree of CA2 asymmetry. Additionally, 19% of cases revealed a difference in Braak score between the right and left hippocampi. There was a significant difference in CA2 neurofibrillary degeneration (p = 0.0006) and CA2/CA1 ratio (p < 0.0001) when comparing the contralateral sides, but neither right nor left was more consistently affected. These data show the importance of analyzing bilateral hippocampi in the diagnostic evaluation of PART and potentially of other neurodegenerative diseases.
Constrained generative adversarial network ensembles for sharable synthetic medical images
Dikici, Engin , Bigelow, Matthew , Erdal, Barbaros S. , Prevedello, Luciano M. , White, Richard D , Erdal, Barbaros S , Prevedello, Luciano M , White, Richard

Mayo Clinic

Journal of Medical Imaging | April 10, 2021 | Volume: 8 | Issue: 02 | Pages: No page available

10.1117/1.jmi.8.2.024004 | PMID 33855104 Get It

White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline
Vemuri, Prashanthi , Graff‐Radford, Jonathan , Lesnick, Timothy G. , Przybelski, Scott A. , Reddy, Ashritha L, Lowe, Val J. , Mielke, Michelle M. , Petersen, Ronald C. , Jack, Clifford R. , Mielke, Michelle M , Jack, Clifford R , Vemuri, Prashanthi , Reid, Robert I. , Reddy, Ashritha L, Machulda, Mary M. , Knopman, David S.

Mayo Clinic

Brain Communications | April 10, 2021 | Volume: 3 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcab076 | PMID 33937772 Get It

Abstract While cerebrovascular disease can be observed in vivo using MRI, the multiplicity and heterogeneity in the mechanisms of cerebrovascular damage impede accounting for these measures in ageing and dementia studies. Our primary goal was to investigate the key sources of variability across MRI markers of cerebrovascular disease and evaluate their impact in comparison to amyloidosis on cognitive decline in a population-based sample. Our secondary goal was to evaluate the prognostic utility of a cerebrovascular summary measure from all markers. We included both visible lesions seen on MRI (white matter hyperintensities, cortical and subcortical infarctions, lobar and deep microbleeds) and early white matter damage due to systemic vascular health using diffusion changes in the genu of the corpus callosum. We identified 1089 individuals aged ≥60 years with concurrent amyloid-PET and MRI scans from the population-based Mayo Clinic Study of Aging. We divided these into discovery and validation datasets. Using the discovery dataset, we conducted principal component analyses and ascertained the main sources of variability in cerebrovascular disease markers. Using linear regression and mixed effect models, we evaluated the utility of these principal components and combinations of these components for the prediction of cognitive performance along with amyloidosis. Our main findings were (i) there were three primary sources of variability among the CVD measures—white matter changes are driven by white matter hyperintensities and diffusion changes; number of microbleeds (lobar and deep); and number of infarctions (cortical and subcortical); (ii) Components of white matter changes and microbleeds but not infarctions significantly predicted cognition trajectories in all domains with greater contributions from white matter; and (iii) The summary vascular score explained 3–5% of variability in baseline global cognition in comparison to 3–6% variability explained by amyloidosis. Across all cognitive domains, the vascular summary score had the least impact on memory performance (∼1%). Though there is mechanistic heterogeneity in the cerebrovascular disease markers measured on MRI, these changes can be grouped into three components and together explain variability in cognitive performance equivalent to the impact of amyloidosis on cognition. White matter changes represent dynamic ongoing damage, predicts future cognitive decline across all domains and diffusion measurements help capture white matter damage due to systemic vascular changes. Therefore, measuring and accounting for white matter changes using diffusion MRI and white matter hyperintensities along with microbleeds will allow us to capture vascular contributions to cognitive impairment and dementia.
Effect of combined renin angiotensin aldosterone inhibitors and diuretic treatment among patients hospitalized with SARS-CoV-2 Infection COVID-19
Palazzuoli, Alberto , Tecson, Kristen M. , Vicenzi, Marco , D’Ascenzo, Fabrizio, Ferrari, Gaetano Maria De , Monticone, Silvia , Secco, Gioel Gabrio , Tavazzi, Guido , Forleo, Giovanni B. , Severino, Paolo , Fedele, Francesco G. , Rosa, Francesco Giuseppe De , McCullough, Peter Andrew

Mayo Clinic

No container title available | April 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-345834/v1 Get It

Abstract Background: Antecedent use of renin angiotensin aldosterone inhibitors (RAASi) appears crucial to prevent clinical deterioration and protect against cardiovascular and/or thrombotic complications of Coronavirus Disease (COVID-19), for indicated patients. Doubts have been raised about continuing treatment throughout infection, and nothing is known regarding its effect with concomitant medications. Hence, the purpose of this paper is to evaluate the differential effect of RAASi continuation in patients hospitalized with COVID-19 according to diuretic use.Methods: We used the Coracle (epidemiology, clinical characteristics, and therapy in real life patients affected by Sars-Cov-2) multi-center registry, which contains data of hospitalized patients with COVID-19 from 4 regions of Italy. We performed analyses on adult (50+ years) records with admission on/after February 22, 2020 with a known mortality or discharge status as of April 1, 2020. We constructed a multivariable Firth logistic regression model to complete our objective.Results: There were 286 patients in this analysis. Overall, 100 (35.0%) patients continued RAASi and 186 (65%) discontinued. There were 98 patients who were treated with a diuretic; 51 (52%) of those continued RAASi. The in-hospital mortality rates among patients treated with a diuretic and continued vs. discontinued RAASi were 7.8% vs 25.5% (p = 0.0179). There were 188 patients who were not treated with a diuretic; 49 (26.1%) of those continued RAASi. The in-hospital mortality rates among patients who were not treated with a diuretic and continued vs. discontinued RAASi were 16.3% vs 9.4% (p = 0.1827). After accounting for age, congestive heart failure, and coronary heart disease/ischemic heart disease, continuing RAASi decreased the risk of mortality by approximately 72% (OR = 0.28, 95% CI = 0.08 – 0.94, p = 0.0391) for patients treated with diuretics, but did not alter the risk in patients who were not treated with diuretics.Conclusion: Diuretic use in hospitalized patients with COVID-19 who were on RAASi prior to admission was associated with increased risk of in-hospital mortality. Whether this combined therapy increases risk or is the reflection of a more severe presentation deserves further investigation. Continuing RAASi therapy in patients concomitantly treated with diuretics was associated with reduced in-hospital mortality.
Crossing the Carotid Siphon: Techniques to Facilitate Distal Access in Tortuous Anatomy: 2-Dimensional Operative Video
Hadley, Caroline , Burkhardt, Jan‐Karl , Johnson, Jeremiah N., Kan, Peter , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Levitt, Michael R. , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , White, Jonathan, Ogilvy, Christopher S. , Levitt, Michael R , Burkhardt, Jan-Karl , Schirmer, Clemens M , Ogilvy, Christopher S , Burkhardt, Jan‐Karl , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levy, Elad I. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Tawk, Rabih G. , Thomas, Ajith J , White, Jonathan A.

Mayo Clinic

Operative Neurosurgery | April 6, 2021 | Volume: 21 | Issue: 1 | Pages: E41-E42

10.1093/ons/opab084 | PMID 33822191 Get It

Abstract As capabilities for endovascular treatment of intracranial vascular pathologies continue to expand, the need for access to the distal internal carotid artery with rigid support catheter systems continues to increase. One of the dominant factors limiting this access is patient anatomy, specifically vessel tortuosity. Increased tortuosity of the carotid siphon is a frequently encountered anatomic variant and may complicate endovascular procedures in adults and children. 1,2 Failed attempts to navigate the carotid siphon with a distal access catheter carry a risk of vessel injury and treatment failure. For this reason, techniques that aid in supporting safe advancement of a distal access catheter across a tortuous carotid siphon are essential. 3,4 In this video, we demonstrate 2 ways in which this may be accomplished. The first technique uses a larger diameter microcatheter, such as the AXS Offset catheter (Stryker, Kalamazoo, Michigan), to increase support for the distal access catheter, while the second uses a buddy wire technique to accomplish this increased support. Both of these techniques can help increase the safety of navigating a tortuous carotid siphon and increase the likelihood of successful treatment. The procedures shown were performed with the informed consent of the patients.
The low excretor phenotype of glutaric acidemia type I is a source of false negative newborn screening results and challenging diagnoses
Guenzel, Adam J. , Scott, Anna I. , Lam, Christina , Chang, Irene J. , Thies, Jenny , Pichurin, Pavel N. , Laxen, William , Raymond, Kimiyo , Gavrilov, Dimitar K. , Oglesbee, Devin , Rinaldo, Piero, Matern, Dietrich , Tortorelli, Silvia , Oglesbee, Devin , Thies, Jenny M , Hall, Patricia , Ferreira, Carlos R

Mayo Clinic

JIMD Reports | April 6, 2021 | Volume: 60 | Issue: 1 | Pages: 67-74

10.1002/jmd2.12217 | PMID 34258142 Get It

AbstractBackgroundGlutaric acidemia type I (GA1) is an organic acidemia that is often unrecognized in the newborn period until patients suffer an acute encephalopathic crisis, which can be mistaken for nonaccidental trauma. Presymptomatic identification of GA1 patients is possible by newborn screening (NBS). However, the biochemical “low‐excretor” (LE) phenotype with nearly normal levels of disease metabolites can be overlooked, which may result in untreated disease and irreversible neurological sequelae. The LE phenotype is also a potential source of false negative (FN) NBS results that merits further investigation.MethodsSamples from six LE GA1 patients were analyzed by biochemical and molecular methods and newborn screen outcomes were retrospectively investigated.ResultsFive LE GA1 patients were identified that had normal NBS results and three of these presented clinically with GA1 symptoms. One additional symptomatic patient was identified who did not undergo screening. Semiquantitative urine organic acid analysis was consistent with a GA1 diagnosis in two (33%) of the six patients, while plasma glutarylcarnitine was elevated in four (67%) of the six and urine glutarylcarnitine was elevated in four (80%) of five patients. Five GCDH variants were identified in these patients; three of which have not been previously linked to the biochemical LE phenotype.ConclusionsThe data presented here raise awareness of potential FN NBS results for LE GA1 patients. The LE phenotype is not protective against adverse clinical outcomes, and the possibility of FN NBS results calls for high vigilance amongst clinicians, even in the setting of a normal NBS result.
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
Venner, Christopher P. , Offner, Fritz , White, Darrell , Karlin, Lionel, Benboubker, Lotfi , Rigaudeau, Sophie , Rodon, Philippe, Voog, Éric , Suzuki, Kenshi , Zhang, Xiaoquan , Twumasi‐Ankrah, Philip, Rifkin, Robert M. , Kumar, Shaji , Richardson, Paul G. , Benboubker, Lotfi , Voog, Eric , Yoon, Sung-Soo , Suzuki, Kenshi , Shibayama, Hirohiko , Yung, Godwin , Kumar, Shaji K , Rajkumar, S Vincent , Facon, Thierry T.F. , Bahlis, Nizar Jacques , Karlin, Lionel , Yoon, Sung‐Soo , Shibayama, Hirohiko , Yung, Godwin , Moreau, Philippe , Lonial, Sagar , Richardson, Paul Gerard Guy , Rajkumar, S. Vincent

Mayo Clinic

Blood | March 24, 2021 | Volume: 137 | Issue: 26 | Pages: 3616-3628

10.1182/blood.2020008787 | PMID 33763699 Get It

Abstract Continuous lenalidomide-dexamethasone (Rd)-based regimens are among the standards of care in transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients. The oral proteasome inhibitor ixazomib is suitable for continuous dosing, with predictable, manageable toxicities. In the double-blind, placebo-controlled TOURMALINE-MM2 trial, transplant-ineligible NDMM patients were randomized to ixazomib 4 mg (n = 351) or placebo (n = 354) plus Rd. After 18 cycles, dexamethasone was discontinued and treatment was continued using reduced-dose ixazomib (3 mg) and lenalidomide (10 mg) until progression/toxicity. The primary endpoint was progression-free survival (PFS). Median PFS was 35.3 vs 21.8 months with ixazomib-Rd vs placebo-Rd, respectively (hazard ratio [HR], 0.830; 95% confidence interval, 0.676-1.018; P = .073; median follow-up, 53.3 and 55.8 months). Complete (26% vs 14%; odds ratio [OR], 2.10; P < .001) and ≥ very good partial response (63% vs 48%; OR, 1.87; P < .001) rates were higher with ixazomib-Rd vs placebo-Rd. In a prespecified high-risk cytogenetics subgroup, median PFS was 23.8 vs 18.0 months (HR, 0.690; P = .019). Overall, treatment-emergent adverse events (TEAEs) were mostly grade 1/2. With ixazomib-Rd vs placebo-Rd, 88% vs 81% of patients experienced grade ≥3 TEAEs, 66% vs 62% serious TEAEs, and 35% vs 27% TEAEs resulting in regimen discontinuation; 8% vs 6% died on study. Addition of ixazomib to Rd was tolerable with no new safety signals and led to a clinically meaningful PFS benefit of 13.5 months. Ixazomib-Rd is a feasible option for certain patients who can benefit from an all-oral triplet combination. This trial was registered at www.clinicaltrials.gov as #NCT01850524.
Skin cancer in non‐white liver transplant recipients: Mayo Clinic experience
Tolaymat, Leila , Reimer, Danielle , Feig, Joshua, Gillis, Melinda S. , Speicher, Leigh L. , Haga, Claire , Gabriel, Emmanuel , Heckman, Michael G. , Yin, Mingyuan , Fosko, Scott W. , Dawson, Nancy L. , Tolaymat, Leila M , Reimer, Danielle K , Haga, Claire B , Gabriel, Emmanuel M , Keaveny, Andrew P , Dawson, Nancy L , Heckman, Michael G , Keaveny, Andrew P.

Mayo Clinic

International Journal of Dermatology | March 20, 2021 | Volume: 60 | Issue: 8 | Pages: 986-990

10.1111/ijd.15519 | PMID 33742703 Get It

Abstract Background Limited data are available on the development of skin cancer and the associated risk factors for non‐White liver transplant (LT) recipients. The aim of this study is to determine the incidence of newly diagnosed skin cancer postoperatively and to identify the risk factors for the development of skin cancer in non‐White LT recipients. Methods We conducted an initial retrospective chart review of non‐White LT patients who received a transplant at our center between January 1, 2011, and December 31, 2013. Results Of the 96 patients in the study cohort, 32% were Black, 17% were Asian, 15% were White Hispanic, and 10% were Black Hispanic. One patient had a history of nonmelanoma skin cancer before transplant. No skin cancers were diagnosed during follow‐up (median, 1.3 years; range, 17 days to 8.6 years). Conclusion Our center’s experience is consistent with the literature and suggests that the incidence of newly diagnosed skin cancer in non‐White liver transplant recipients is low. Longer follow‐up may provide additional insights into the specific risk factors for the posttransplant development of skin cancer.